Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, PD, and Food Effect of HSK39297 in Healthy Subjects
NCT06350279Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in glomerular disease and paroxysmal nocturnal hemoglobinuria (PNH) comparing HSK39297 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2023; status: completed.
02
Drugs
ciprocopan
03
Conditions
glomerular diseaseparoxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06350279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350279.